1.
Bioorg Med Chem Lett
; 12(15): 2019-22, 2002 Aug 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12113832
RESUMO
The development of potent and selective urokinase-type plasminogen activator (uPA) inhibitors based on the lead molecule 2-(2-hydroxy-3-ethoxyphenyl)-1H-benzimidazole-5-carboxamidine (3a) is described.